Avalo Therapeutics
AVTX
84 hedge funds and large institutions have $361M invested in Avalo Therapeutics in 2025 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 28 increasing their positions, 13 reducing their positions, and 15 closing their positions.
223% more capital inflows, than outflows
Capital inflows: $116M | Capital outflows: $35.9M
120% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 15
115% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 13
81% more call options, than puts
Call options by funds: $6.05M | Put options by funds: $3.35M
42.19% more ownership
Funds ownership: 141.47% → 183.66% (+42%)
27% more funds holding
Funds holding: 66 → 84 (+18)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.82M |
| 2 |
Jennison Associates
New York
|
+$8.03M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$7.62M |
| 4 |
Soleus Capital Management
Greenwich,
Connecticut
|
+$7.46M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$7.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.2M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.38M |
| 3 |
Silverarc Capital Management
Boston,
Massachusetts
|
-$3.32M |
| 4 |
OrbiMed
New York
|
-$2.73M |
| 5 |
Ally Bridge Group
New York
|
-$2.26M |
AVTX Hedge Fund Activity: Q4 2025 in Review
84 of the 8,302 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2025, worth a combined $361M — up 85% from $195M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new AVTX positions and 15 closed out — a net gain of 18 holders — while 28 added to existing stakes and 13 trimmed.
The largest buyer was Millennium Management, adding an estimated $8.82M. The largest seller was Point72 Asset Management, cutting an estimated $7.2M.
- 84 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2025, up from 66 in Q3 2025.
- Funds reported $361M of Avalo Therapeutics stock for Q4 2025, up 85% quarter-over-quarter.
- 33 funds opened new Avalo Therapeutics positions in Q4 2025 and 15 closed out, a net change of +18 holders.
- The largest Avalo Therapeutics buyer in Q4 2025 was Millennium Management, an estimated $8.82M added.
- The largest Avalo Therapeutics seller in Q4 2025 was Point72 Asset Management, an estimated $7.2M sold.
Based on aggregated 13F filings for Q4 2025.